A Phase I Pharmacokinetic Study of MABp1 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2017
Price : $35 *
At a glance
- Drugs Bermekimab (Primary)
- Indications Acne vulgaris; Cachexia; Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
- Focus Pharmacokinetics; Registrational
- Sponsors XBiotech
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 22 Feb 2017 According to a XBiotech media release, dosing of subjects has been completed in this trial.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting based on announcement of dosing completion in an XBiotech media release.